Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) - Drugmaker Novo Nordisk expects a recovery of Wegovy weight-loss drug sales in the United States once a ban on compound copycats is enforced this month,

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on Thursday.

Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving the way for a sales rebound later this year.